Atea says Phase 3 C-BEYOND trial shows hepatitis C combo bemnifosbuvir/ruzasvir matches Epclusa on cure rates

• Atea Pharmaceuticals reported positive topline results from its Phase 3 C-BEYOND North America trial of bemnifosbuvir/ruzasvir for chronic hepatitis C.
• The regimen met the primary and secondary endpoints, matching a standard-of-care therapy in a head-to-head study.
• Results support an 8-week course for patients without cirrhosis, positioning the program as a potential shorter-duration option in a large segment.
• The study showed a comparable safety profile, with no drug-related serious events or early discontinuations reported.
• Detailed results are slated for future medical conferences and peer-reviewed publication; a second Phase 3 readout outside North America is expected in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.